<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586648</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6267</org_study_id>
    <nct_id>NCT03586648</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 2</brief_title>
  <official_title>Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-masked, randomized-controlled, dispensing clinical trial. A total of
      approximately 60 eligible hyperopic subjects will be targeted to complete this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">August 20, 2018</completion_date>
  <primary_completion_date type="Actual">August 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vision Scores</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision Scores Comparison Between Test and Control</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Test/Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A Multifocal</intervention_name>
    <description>TEST Lens</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
    <other_name>JJVC Investigational Multifocal Contact Lens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A Sphere</intervention_name>
    <description>TEST Lens Sphere</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
    <other_name>ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A Multifocal</intervention_name>
    <description>CONTROL Lens</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
    <other_name>1-Day Acuvue Moist Brand Multifocal Contact Lens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A Sphere</intervention_name>
    <description>CONTROL Lens Sphere</description>
    <arm_group_label>Control/Test</arm_group_label>
    <arm_group_label>Test/Control</arm_group_label>
    <other_name>1-Day Acuvue Moist Brand Contact Lens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potential subjects must satisfy all the following criteria to be enrolled in the
             study:

               1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
                  receive a fully executed copy of the form.

               2. The subject must appear able and willing to adhere to the instructions set forth
                  in this clinical protocol.

               3. The subject must be between 40 and 70 years of age (inclusive).

               4. The subject's distance spherical equivalent refraction must be in the range of
                  -1.25 D to -3.75 D in each eye.

               5. The subject's refractive cylinder must be ≤0.75 D in each eye.

               6. The subject's ADD power must be in the range of +0.75 D to +2.50 D.

               7. The subject must have distance best corrected visual acuity of 20/20-3 or better
                  in each eye.

               8. Subjects must own a wearable pair of spectacles if required for their distance
                  vision.

               9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn
                  lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1
                  month of more duration).

              10. The subject must either already be wearing a presbyopic contact lens correction
                  (e.g., reading spectacles over contact lenses, multifocal or monovision contact
                  lenses, etc.) or if not respond positively to at least one symptom on the
                  &quot;Presbyopic Symptoms Questionnaire&quot;.

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Currently pregnant or lactating.

               2. Any active or ongoing ocular or systemic allergies that may interfere with
                  contact lens wear.

               3. Any active or ongoing systemic disease, autoimmune disease, or use of medication,
                  which may interfere with contact lens wear. This may include, but not be limited
                  to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea,
                  Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious
                  diseases (e.g. hepatitis, tuberculosis).

               4. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization,
                  corneal staining, tarsal abnormalities or bulbar injection, or any other corneal
                  or ocular abnormalities which would contraindicate contact lens wear.

               5. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma,
                  history of recurrent corneal erosions.

               6. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy,
                  PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.).

               7. A history of amblyopia, strabismus or binocular vision abnormality.

               8. Any current ocular infection or inflammation.

               9. Any current ocular abnormality that may interfere with contact lens wear.

              10. Use of any of the following oral medications within 1 week prior to enrollment:
                  oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical
                  scopolamine, oral antihistamines (e.g., Chlor-Trimeton, and Benadryl), systemic
                  steroids.

              11. Use of any ocular medication, with the exception of rewetting drops.

              12. History of herpetic keratitis.

              13. Participation in any contact lens or lens care product clinical trial within 30
                  days prior to study enrollment.

              14. Employee or immediate family member of an employee of clinical site (e.g.,
                  Investigator, Coordinator, Technician).

              15. Any known hypersensitivity or allergic reaction to Optifree®Replenish®
                  multipurpose care solution or Eye-Cept® rewetting drop solution.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Golden Optometric Group</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. James E. Weber</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maitland Vision Center</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Golden, OD</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Reserve Vision Care</name>
      <address>
        <city>Beechwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Procare Vision Center</name>
      <address>
        <city>Granville</city>
        <state>Ohio</state>
        <zip>43023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <results_first_submitted>April 10, 2020</results_first_submitted>
  <results_first_submitted_qc>April 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2020</results_first_posted>
  <disposition_first_submitted>August 20, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 27, 2020</disposition_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03586648/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 71 subjects were enrolled in this study of which, 70 subjects were dispensed at least 1 study lens, 1subject failed to meet all eligibility criteria. Of those dispensed a study lens, 61 subjects completed the study while, 9 were discontinued from the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Test/Control</title>
          <description>Subjects that were randomized to receive the Test lens in both eyes during the first period and the Control lens in both eyes during the second period.</description>
        </group>
        <group group_id="P2">
          <title>Control/Test</title>
          <description>Subjects that were randomized to receive the Control lens in both eyes during the first period and the Test lens in both eyes during the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study related symptoms or complaints</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dispensed Subjects</title>
          <description>All subjects dispensed at least one study lens.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vision Scores</title>
        <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>All subjects that completed the study without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Subjects that wore the Test lens in the study.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects that wore the Control lens in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Scores</title>
          <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>All subjects that completed the study without a major protocol deviation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="13.68"/>
                    <measurement group_id="O2" value="55.3" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="22.77"/>
                    <measurement group_id="O2" value="41.8" spread="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Data only from the first period will be used if period effect is significant.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistically superiority will be concluded if the lower limit of the confidence intervals of the Test lens is greater than 32 points.</non_inferiority_desc>
            <param_type>Least-square Mean</param_type>
            <param_value>39.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.7</ci_lower_limit>
            <ci_upper_limit>45.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vision Scores Comparison Between Test and Control</title>
        <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>All subjects that completed the study without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Subjects that wore the Test lens in the study.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects that wore the Control lens in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Scores Comparison Between Test and Control</title>
          <description>Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>All subjects that completed the study without a major protocol deviation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="13.68"/>
                    <measurement group_id="O2" value="55.3" spread="22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="22.77"/>
                    <measurement group_id="O2" value="41.8" spread="14.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority of the Test lens relative to the Control will be concluded if the lower confidence limit of LSM difference is above the non-inferiority margin -5.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Statistically superiority will be concluded if the lower limit of the confidence intervals of the Test lens is greater than -5 points.</non_inferiority_desc>
            <param_type>Least-square Mean Difference</param_type>
            <param_value>-11.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.7</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
            <estimate_desc>Mean difference was calculated as Test minus Control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 4 weeks per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Subjects that wore the Test lens during either period of the study.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects that wore the Control lens during either period of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>If there is a significant sequence effect in the analysis model for vision scores, an analysis will be performed using data from period 1 of the study. All conclusions are based on period 1.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Karkkainen, OD, MS, FAAO- Sr. Principal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>904-443-3402</phone>
      <email>TKarkkai@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

